The use of induced pluripotent stem cells in drug development (Q37856714)

24 August 2017

1 reference

title

The use of induced pluripotent stem cells in drug development (English)

1 reference

24 August 2017

H Inoue

1

1 reference

24 August 2017

S Yamanaka

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

23 March 2011

1 reference

Clinical Pharmacology & Therapeutics

24 August 2017

published in

1 reference

24 August 2017

volume

89

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

655-661

1 reference

Establishment in culture of pluripotential cells from mouse embryos

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Embryonic stem cell lines derived from human blastocysts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Induced pluripotent stem cell lines derived from human somatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Promotion of direct reprogramming by transformation-deficient Myc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Direct reprogramming 101.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

A core Klf circuitry regulates self-renewal of embryonic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

KLF4 and PBX1 directly regulate NANOG expression in human embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Linking the p53 tumour suppressor pathway to somatic cell reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Directed differentiation of human-induced pluripotent stem cells generates active motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Generation of insulin-secreting islet-like clusters from human skin fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Generation of functional human hepatic endoderm from human induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Induction and isolation of vascular cells from human induced pluripotent stem cells--brief report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Stem cell pluripotency: a cellular trait that depends on transcription factors, chromatin state and a checkpoint deficient cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Variation in the safety of induced pluripotent stem cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Status of genomic imprinting in human embryonic stem cells as revealed by a large cohort of independently derived and maintained lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Marked differences in differentiation propensity among human embryonic stem cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Clone- and gene-specific aberrations of parental imprinting in human induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Transcriptional signature and memory retention of human-induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

iPSC lines that do not silence the expression of the ectopic reprogramming factors may display enhanced propensity to genomic instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Generation of induced pluripotent stem cells using recombinant proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Lab-specific gene expression signatures in pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Disease-specific induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Induced pluripotent stem cells from a spinal muscular atrophy patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

High-content screening of small compounds on human embryonic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

High content screening: seeing is believing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Human pluripotent stem cells in drug discovery and predictive toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Recent stem cell advances: induced pluripotent stem cells for disease modeling and stem cell-based regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Combination of functional cardiomyocytes derived from human stem cells and a highly-efficient microelectrode array system: an ideal hybrid model assay for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

What can pluripotent stem cells teach us about neurodegenerative diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Induced pluripotent stem cell technology for the study of human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Targeted gene modifications in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Genetic modification of human embryonic stem cells for derivation of target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Technical challenges in using human induced pluripotent stem cells to model disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Patient-specific pluripotent stem cells become even more accessible

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Reprogramming of human peripheral blood cells to induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Reprogramming of T cells from human peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Epigenetic memory in induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Ventricular arrhythmogenesis: insights from murine models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Translating preclinical insights into effective human trials in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Design, power, and interpretation of studies in the standard murine model of ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

The promise of human induced pluripotent stem cells for research and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

Obstacles and opportunities in new drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

7 January 2021

The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

7 January 2021

Stem cells and drug discovery: the beginning of a new era?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

7 January 2021

The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

7 January 2021

Early TCR expression and aberrant T cell development in mice with endogenous prerearranged T cell receptor genes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

7 January 2021

Human stem cells and drug screening: opportunities and challenges

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.38

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.38

1 reference

24 August 2017

1 reference